24^th Drug Discovery
Innovation Programme

Lonza is one of the world’s largest healthcare manufacturing organizations. Working across five continents, our global community of around 18,000 colleagues helps pharmaceutical, biotech and nutrition companies to bring their treatments to market. United by our vision to bring any therapy to life, we support our customers with a combination of technological insight, world-class manufacturing, scientific expertise, process excellence and innovation. Our work enables our customers to develop and commercialize their therapeutic discoveries, allowing their patients to benefit from life-saving and life-enhancing treatments. Our business is structured to meet our customers' complex needs across four divisions: Biologics, Small Molecules, Cell & Gene, and Capsules & Health Ingredients. Our company generated sales of CHF 3.1 billion with a CORE EBITDA of CHF 893 million in Half-Year 2024. Find out more at www.lonza.com.

Selvita Group has broad expertise and track record in oncology, inflammation, fibrosis, anti-infectives, respiratory diseases and CNS. The company offers drug discovery support at every stage of the early discovery phase up to the preclinical development. Selvita specializes in a variety of drug discovery processes from in silico drug design and synthesis of a target-focused library, SAR and ADME-driven lead optimization and toxicity prediction, followed by complex preclinical in vitro and in vivo pharmacology, structural biology, all tailored to the customer’s needs.

Inoviem Scientific is a bioanalytical Private Research Organization (established in 2011 in Strasbourg). We deliver enabling information to secure drug discovery programs and to take informed decision by closing the gap between preclinical and clinical development. Inoviem has established label-free platforms working on diseased tissues and delivering experimentally validated clinical target engagement, Mode of Action, Indication prioritization and predictive biomarkers through patient stratification. Inoviem has direct access to patients in all human indications, allowing the collections of fresh pathological samples for ex-vivo pharmacology and personalized medicine. Its 13 years of experience in personalized medicine combined with its groundbreaking technology platforms allow Inoviem to unlock the potential of any program in development for pharma and biotech, accelerating and securing their drug development process.

Our mission at Causaly is to redefine the boundaries of human discovery by harnessing transformative AI technologies. Founded in 2018, Causaly’s unique AI platform is a powerful catalyst for the modern Life Sciences research organization, reshaping how data is found, analyzed and applied in critical decision-making processes in drug discovery and development. Supporting a broad range of complex knowledge workflows, our platform accelerates the journey from bench research and laboratory insights to the launch of life-changing therapies.

IRBM is a scientific contract research organization (CRO) that stands at the forefront of drug discovery, leveraging a single, unified research facility to accelerate team-based breakthroughs and improve efficiencies from concept to candidate. With a history of contributing to several approved drugs, and its own internal pipeline of oncology and other therapeutic assets, IRBM is powered by deep collaborations and decades of expertise from leading global institutions. Their comprehensive in-house capabilities assist partners in achieving key milestones and progressing towards clinical readiness, positioning IRBM as a major player in driving innovation in the pharmaceutical and biotech fields.

Sterling Pharma Solutions is a global contract development and manufacturing organisation (CDMO) with more than 50 years’ experience in providing small molecule API development and manufacturing services to the pharmaceutical industry, specialising in handling challenging chemistries. Sterling manages the most complex API and API intermediate challenges from proof-of-concept to commercial manufacture, as well as Antibody Drug Conjugate (ADC) development and manufacturing services. At Sterling we believe that whilst science can be complex, partnerships should be simple. That’s why we have redefined the CDMO experience with a partnership centred approach marked by transparency, collaboration and trust; a Partnership Development and Manufacturing Organisation (PDMO). Sterling has five facilities employing more than 1,300 people: its HQ in Cramlington, UK and a facility in Ringaskiddy, Ireland; two sites in the US, in Cary, North Carolina and Germantown, Wisconsin; and a dedicated bioconjugation and ADCs facility in Deeside, Wales.

For more information visit www.sterlingpharmasolutions.com

TCG Lifesciences Pvt. Limited is a leading global CRO and CDMO delivering innovative R&D services to pharmaceutical, biotech and related industries.

Phenocell is a Partner Research Organisation committed to helping R&D departments reach their objectives with more speed and accuracy. Our approach is based on the Nobel Prize winning technology of iPS cells and the possiblity to obtain human cells with controled genetic background in unlimited number. We specialize in two fields, dermo-cosmetics and ophthalmology. For retinal disorders, our unique expertise will be instrumental in identifying compounds with neuroprotective properties and deciphering their in-depht mechanisms of action, thus facilitating the development of future drugs with confidence and high relevance to human pathologies. For the dermo-cosmetic sector, a wide range of vitro approaches will help qualifying compounds in e.g. acne and pigmentation disorders, aging and sensoriality. Our researcher teams develop precise and relevant bioassays for early pre-clinical drug discovery and development that will ultimately lead to new drugs and therapies for pathologies with unmet medical need.

Promethean Drug Ideas is a scientific consultation firm, well oriented to global drug discovery approaches in Precision Medicine and Chronic diseases. We have extensive expertise deep diving into ocean of cutting-edge science literature which is unstructured, complex, and constantly evolving, with intense depth and breadth to bring it to your door step in “Ready to apply” form to facilitate your scientific decisions and research strategies. We provide complete 360-degree, deepest dived, scientific assessments, critical insights, and opinions in precise niche area of your interest efficiently. Our expertise includes Translational Science, AI Enabled Drug Discovery, Drug Design Approaches, First-in-class and Best-in-class Target Assessments, SWOT analysis, Combinatorial Targeting, Competitive Pipelines of varied therapeutic modalities - Small & Large molecules, Nucleic Acids, Peptides, Cell and Gene therapies, Drug Repurposing, Asset in-licensing, out-licensing, Biomarkers, Early Human POM/POC studies & Identification of Special Skilled CROs TAs: Oncology/Immuno-oncology, Inflammation, Autoimmune, Cardiometabolic and Neuro-degeneration, Infectious Disease, Rare Diseases.

Sino Biological – Your recombinant protein, antibody, and CRO service provider.

Sino Biological, Inc. boasts a workforce of over 1000 employees and is headquartered in Beijing, China with subsidiaries in the United States, Europe, Japan, Suzhou, and Taizhou, China. As the only subsidiary in Europe, Sino Biological Europe GmbH is located in Frankfurt with a local sales and service team as well as our comprehensive protein inventory. These facilities enable Sino Biological to deliver high-quality products and services with competitive lead times to our European customers. With the largest validated recombinant protein bank (6500+), Sino Biological offers an extensive selection of antigens including viral proteins, cytokines, growth factors, immune checkpoints, antigens for therapeutic targets, Fc receptors, and biomarker proteins. Furthermore, we have independently developed a comprehensive collection of high-quality monoclonal mouse and rabbit antibodies, including neutralizing antibodies and antibody pairs, to support scientific and clinical research. As a specialist in protein recombinant expression and antibody development, Sino Biological is also the one-stop shop for robust customized CRO services. In addition, we have developed several cutting-edge technologies, featuring VLPs-based membrane protein expression, nanobody production, Beacon-based single-cell sorting antibody development, antibody humanization, anti-idiotypic antibody development, AI-powered antibody affinity maturation, and Cell-free protein expression platform, to accelerate pharmaceutical and pre-clinical antibody drug development,

Univo IRB, formerly Principal IRB, is your next generation institutional review board (IRB) specializing in the ethical review of all phases of human research that is centered around the patient. At Univo, we are driven by our common mission: to unify clinical research with our passion for patient protection, education, and advocacy. We are passionate about using our role in research to bring better patient experiences and drive more people to participate in clinical trials. We offer agile study approaches, expert solutions powered by industry-leading study technology, and a service-first approach. Univo IRB holds accreditation through the Association for the Accreditation of Human Research Protection Programs (AAHRPP). Univo is also one of the first to bring a purpose-built tool for central IRBs on today’s tech platforms. One that will modernize the submission and review process making it convenient to work with an IRB and get the information you need.

Sanyou Biopharmaceuticals Co., Ltd. is a world-leading high-tech biotechnology enterprise focusing on R&D and services of innovative biologic drugs. Sanyou is committed to bridge drug R&D and all-life-cycle manufacture supply chain, and has built the 4C business patterns that integrate "differentiated CRO, integrated CDO, innovative CPO and characteristic CRS”, to accomplish the mission “to make the R&D easy for innovative biologics”.

WestRock is a global leader in sustainable, fibre-based secondary packaging solutions. Within our Consumer Packaging division, we operate a specialised business unit focused solely on Pharmaceutical & Clinical, our dedicated team providing packaging solutions for clinical trials and patient medication adherence. WestRock partners with our customers to provide printed packaging solutions for their Clinical Trial and Adherence focused Child Resistant Senior Friendly packaging needs. We offer a complete range of innovative packaging including multi-vial and injector cartons, complex calendarized blister packs, and SMART digitally and electronically enabled platforms. Our business is packaging but our strength is developing solutions to meet client requirements. We focus on innovation and leverage our extensive knowledge of the clinical trial and drug launch process to create package solutions that optimise supply chain whilst improving patient adherence. This is what our customers have come to expect and value – and this is what we commit to deliver.
Clinical Trial Packaging Solutions | WestRock

Eurofins Advinus is your trusted partner for specialised discovery, preclinical and early clinical development programs. With over 30 years of GLP experience we have a proven track record of successfully delivering results within defined timelines and highest level of quality. We offer integrated, innovative fast-paced drug discovery services across various therapeutic areas and target classes. Our services include Discovery Chemistry, Discovery Biology, ADME/DMPK, full range of safety assessment studies along with Chemistry Manufacturing and Controls (CMC) services. We can help advance and accelerate your R&D programs cost-efficiently and with highly informed decisions towards the next critical milestone.

FORMULATRIX® collaborates with researchers to simplify the preparation and analysis of proteins and nucleic acids by designing solutions without boundaries and bringing novel cutting-edge technology to the life science industry. We supply software and laboratory automation solutions to the top pharmaceutical companies and leading academic research institutions working in a variety of genomics and proteomics applications. Our team works tirelessly to simplify life science workflows to save you time, money, and resources so you can achieve your next breakthrough. We are committed to researchers, their labs, and to the scientific discoveries that will improve the lives of generations to come.

Myonex is a global complete clinical trial solutions provider. For over 35 years, we have been the leading global clinical trial supply company and we have expanded our service portfolio to offer complete solutions around clinical trials for our partners. We at Myonex add value to our clients by helping them always be prepared for what is next in their clinical trials. Our goal each day, every day is to make sure our partners have whatever they need when and where they need it to execute a successful clinical trial, while also minimizing delays, unnecessary costs, and surprises.

Analog Devices, Inc. (NASDAQ: ADI) is a global semiconductor leader that bridges the physical and digital worlds to enable breakthroughs at the Intelligent Edge. ADI combines analog, digital, and software technologies into solutions that help drive advancements in digitized factories, mobility, and digital healthcare, combat climate change, and reliably connect humans and the world. We are at the forefront of an ecosystem that is driving healthcare forward to deliver life-changing solutions for all. Our technology captures clinical-grade data and turns it into simple, trusted insights for remote patient monitoring. We have decades of experience in the healthcare industry as a key technology provider for CT machines, MRI machines, digital x-ray, handheld ultrasound, vital signs monitoring, and much more. By making care possible in more places and delivering insight at the Intelligent Edge, we are helping to improve patient outcomes.

Learn more at www.analog.com and on LinkedIn and Twitter.

Biorasi is a customer-focused, full-service, contract research organization (CRO) that delivers fast and flexible solutions across global clinical trials to maximize speed-to-market for its sponsors. As the leader in clinical trials for dermatology, neurology, oncology, and rare disease, Biorasi sets new benchmarks for speed, agility, and quality in patient enrollment, decentralized trials, and data sciences.

Oracle Life Sciences is a global leader in cloud technology, pharmaceutical research, and consulting, trusted by professionals in both large and emerging companies engaged in clinical research and pharmacovigilance, throughout the therapeutic development lifecycle, including pre- and post-drug launch activities. Oracle Life Sciences is committed to supporting clinical development and leveraging real-world evidence to deliver innovation and accelerate advancements – empowering the life sciences industry to help improve patient outcomes. Learn more at http://oracle.com/lifesciences.

Artyc designs battery-powered coolers that offer precision and reliability for the transport of temperature-sensitive clinical supplies. Our coolers have built-in sensors for monitoring temperature, location, and vibration, ensuring the integrity and traceability of vital trial materials.

As a global leader in laboratory and clinical technologies, Agilent is committed to helping scientists bring great science to life. As they pursue small, everyday advances and life-changing discoveries, we provide trusted answers to scientists' and clinicians’ most critical questions and challenges. Leveraging more than 50 years of expertise, we create advanced instruments, software, and consumables supported by teams of highly skilled and knowledgeable people. Our comprehensive solutions produce the most accurate results as well as optimal scientific, economic, and operational outcomes. By working collaboratively with our customers and supporting their needs, we help them bring great science to food, pharma, environment, energy, chemical, academic research, and clinical fields.

Sapio Sciences' mission is to improve life in the lab - because science is complex, Sapio makes technology simple. Sapio is a global business offering an all-in-one science-aware (TM) lab informatics platform combining cloud-based LIMS, ELN, and data solutions. Sapio serves some of the largest global and niche brands, including biopharma, CRO's and clinical diagnostic labs across NGS genomic sequencing, bioanalysis, bioprocessing, stability, clinical, histopathology, drug research, and in vivo studies. Our customers love Sapio's platform because it is robust, scalable, and with no-code configuration, can quickly adapt to meet unique needs.